** Shares of drug developer Kymera Therapeutics KYMR.O rise 39.16% to $41.25 premarket
** Company says its experimental oral drug showed robust STAT6 degradation in blood and skin in early-stage trial
** The drug, KT-621, targets STAT6 — a signaling protein that plays a key role in immune response
** Company says results exceeded 90% STAT6 degradation target even at single doses as low as 6.25 mg
** KT-621 impact on biomarkers of Th2 immune response were in line or superior to Sanofi SASY.PA and Regeneron's REGN.O Dupixent - KYMR
** The study finds that KT-621 was as safe as the placebo, with no severe adverse events
** Up to last close, Kymera stock down ~26% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.